Open AccessGuideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China
Author(s) -
Yu Wang,
Jianmin Zhang,
Wenbin Li,
Taipeng Jiang,
Songtao Qi,
Zhongping Chen,
Jae-Heon Kang,
Lei Huo,
Yunjie Wang,
Qichuan Zhuge,
Guodong Gao,
Yuping Wu,
Hua Feng,
Gang Zhao,
Xiaopeng Yang,
Hui Zhao,
Yirong Wang,
Hui Yang,
Dezhi Kang,
Jun Su,
Li Liang,
Chuanlu Jiang,
Gang Li,
Yongming Qiu,
Weimin Wang,
Wang Handong,
Zaihua Xu,
Liwei Zhang,
Renzhi Wang
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0435
Subject(s) - medicine , temozolomide , regimen , guideline , dose , concomitant , glioblastoma , oncology , surgery , chemotherapy , pathology , cancer research
Aims: To determine how consistently Chinese glioblastoma multiforme (GBM) patients were treated according to the Stupp regimen. Patients and methods: The proportion of treatments conforming to the Stupp regimen and reasons for nonconformity were evaluated in 202 newly diagnosed GBM patients. Results: Only 15.8% of GBM patients received treatments compliant with the Stupp regimen. The main deviations were temozolomide dosages >75 mg/m 2 (58/120; 48.3%) and treatment durations <42 days (84/120; 70.0%) in the concomitant phase and temozolomide dosages <150 mg/m 2 (89/101; 88.1%) in the maintenance phase. Median overall survival (27.09 vs 18.21 months) and progression-free survival (14.27 vs 12.10 months) were longer in patients who received Stupp regimen-compliant treatments. Conclusion: Increased conformity to the Stupp regimen is needed for GBM patients in China.